Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences Inc. reported that President and CEO Alexander Cumbo acquired 169,401 restricted stock units (RSUs), each representing one share of common stock. These RSUs relate to performance stock units granted on June 11, 2024, which vest in four 25% performance tranches.
The Board determined that the performance criteria for the second Performance Milestone were met on January 29, 2026. Shares tied to this milestone will vest only if Cumbo continues serving with the company through the Evaluation Date, which is anticipated in the first quarter of 2027.
Solid Biosciences Inc. reported that Chief Technology Officer Paul Herzich acquired 54,925 restricted stock units (RSUs) linked to the company’s common stock as part of his equity compensation. These RSUs were earned under performance stock units (PSUs) originally granted on June 11, 2024.
The PSUs vest in four equal 25% tranches upon achieving independent, pre-set performance milestones tied to business objectives. The Board determined the second milestone was met on January 29, 2026, triggering this 54,925-unit award. These shares will actually vest only if Herzich remains in service on the related Evaluation Date, anticipated in the first quarter of 2027.
Solid Biosciences Inc. reported that CFO & Treasurer Kevin Tan acquired 56,647 restricted stock units tied to prior performance-based awards. Each unit represents a contingent right to receive one share of common stock, bringing his directly held RSU-based position reported in this filing to 56,647 units.
These RSUs relate to performance stock units granted on June 11, 2024, which vest in four equal 25% tranches upon achieving predetermined, non-market and non-financial performance milestones. The second milestone was certified as achieved on January 29, 2026, with the associated shares scheduled to vest only if he remains in service through an evaluation date anticipated in the first quarter of 2027.
Solid Biosciences Inc. reported that Chief Regulatory Officer Jessie Hanrahan acquired 54,925 restricted stock units (RSUs) as a compensation grant. Each RSU represents a contingent right to receive one share of Solid Biosciences common stock.
These RSUs relate to performance stock units (PSUs) granted on June 11, 2024. The PSUs vest in four 25% tranches upon achieving independent, Board‑determined performance milestones that are non‑market and non‑financial. The Board determined that the second performance milestone was met on January 29, 2026, and the related shares will vest subject to continued service through an evaluation date anticipated in the first quarter of 2027.
Solid Biosciences Inc. will hold a virtual 2026 Annual Meeting of Stockholders on June 10, 2026 to vote on director elections, auditor ratification and corporate governance proposals. The Board requests votes to elect three Class II directors—Clare Kahn, Adam Stone and Lynne Sullivan—and to ratify the advisory appointment of Ilan Ganot as a Class I director. The Board also asks stockholders to ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm and to approve an amendment to the Certificate of Incorporation to increase authorized common shares from 240,000,000 to 480,000,000. The Board has set the record date as April 16, 2026 and recommends voting "FOR" each proposal.
Solid Biosciences Inc. reported a technical change to its Board structure. Effective at 4:00 p.m. Eastern Time on April 10, 2026, director Ilan Ganot resigned from the Class III director group and was immediately reappointed as a Class I director.
This adjustment sets both Class I and Class III at three directors each and is described as being for the sole purpose of achieving an equal balance among the Board’s three classes. Mr. Ganot’s new Class I term will run until the 2028 Annual Meeting of Stockholders.
The company plans to ask stockholders at the 2026 Annual Meeting to ratify, on an advisory basis, Mr. Ganot’s appointment as a Class I Director, reflecting its corporate governance focus. His compensation arrangements remain unchanged, and he will not receive any additional compensation for this reclassification.
Solid Biosciences Inc. director Ian F. Smith exercised restricted stock units into common shares. On April 2, 2026 he converted 3,441 restricted stock units into 3,441 shares of common stock at a stated price of $0.00 per share.
The restricted stock units were granted on January 2, 2026 and vest in equal quarterly installments over 12 months from the grant date. Following this transaction, Smith holds 134,705 shares of common stock directly and 10,320 restricted stock units.
Solid Biosciences Inc. is registering up to 42,780,739 shares of its common stock for resale, to be sold from time to time by the selling stockholders named in the prospectus. The registration covers 27,807,482 shares issuable upon exercise of pre-funded warrants issued in the March 2026 private placement.
The prospectus states the company will not receive any proceeds from sales by the selling stockholders. The March 2026 Private Placement closed on March 9, 2026, when the company issued 14,973,257 shares and pre-funded warrants and received gross proceeds of $240.0 million before fees and expenses. Shares outstanding were 98,391,314 as of March 10, 2026.